Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 100 mg Version of Vimpat IV Infusion Now Available in Japan: UCB
June 12, 2020
- Shonan iPark to Launch VC Consortium
June 12, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- Sanofi Rolls Out Soliqua Injection SoloStar for Type 2 Diabetes in Japan
June 10, 2020
- Xofluza Shows Favorable Results in Patients at High Risk of Flu Complications in Global PIII: Shionogi
June 10, 2020
- Japan Ethical Drug Sales Up 2.6% in April: Crecon
June 10, 2020
- Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
June 10, 2020
- Jiangsu Hengrui to Return Telomelysin’s China Rights to Oncolys
June 10, 2020
- Nippon Shinyaku’s DMD Drug Gets Orphan Status in Europe
June 9, 2020
- Evrenzo Shows Non-Inferiority to Nesp in Non-Dialysis CKD Patients
June 9, 2020
- Takhzyro Shows Sustained Effect in Staving Off HAE Attacks
June 9, 2020
- Big 3 Generic Firms Log 5.9% Sales Increase in FY2019, with Contraction in Overseas Business: Jiho Tally
June 9, 2020
- Bayer HIF-PH Inhibitor Molidustat Filed in Japan in Q1
June 9, 2020
- Japan Team to Develop Nafamostat Inhaler Formulation for COVID-19
June 9, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
- Chugai Files FoundationOne as Lynparza CDx for mCRPC
June 8, 2020
- Meiji Pharma Jettisons Nail Ringworm Med ME1111
June 8, 2020
- Opdivo Gets Taiwan Nod for Second-Line Esophageal Cancer
June 8, 2020
- Ono Kicks Off Japan Clinical Study for Pancreatitis Med Foipan for COVID-19
June 8, 2020
- Rakuten Medical, MD Anderson Pair Up on Cancer Photoimmunotherapy
June 8, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…